European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI (y 2)

This press release contains certain forward-looking statements about the potential of prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical compound, there are substantial risks and uncertainties in the process of development, regulatory review, and commercialization. There is no guarantee that the compound will receive regulatory approvals, that the regulatory approvals will be for the indication(s) anticipated by the companies, or that later studies and patient experience will be consistent with study findings to date. There is also no guarantee that the compound will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.

Plavix(R)/Iscover(R) are registered trademarks of sanofi-aventis.

EFIENT(R) is a registered trademark of Eli Lilly and Company in the European Union.

P--LLY

(1) Efient Summary of Product Characteristics.

(2) British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008, http://www.ehnheart.org/files/statistics%202008%20web-161229..., Accessed December 9, 2008.

(3) American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. http://www.americanheart.org/downloadabl.... final.pdf. Accessed December 9, 2008.

(4) WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease. http://www.webmd.com/heart-disease/guide/heart-disease-coron... e. Accessed December 9, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )

Carole Copeland (OUS), Eli Lilly and Company, +1-317-277-3661 - office, or cell, +1-317-610-6196; or Tammy Hull (U.S.A.), Eli Lilly and Company, +1-317-651-9116 - office, or cell, +1-317-614-5132; or Olaf Lamberz, Daiichi Sankyo (Europe GmbH), + 49-89-7808-442 - office; or Kim Wix, Daiichi Sankyo (US), +1-973-695-8338 - office, or cell, +1-908-656-5447; or Shigemichi Kondo, Daiichi Sankyo (Tokyo), +81-3-6225-1126 - office. Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO